...
首页> 外文期刊>International Journal of Nanomedicine >Development of enteric submicron particle formulation of papain for oral delivery
【24h】

Development of enteric submicron particle formulation of papain for oral delivery

机译:木瓜蛋白酶肠溶性亚微米颗粒制剂的研制

获取原文
           

摘要

Background: Particulate systems have received increasing attention for oral delivery of biomolecules. The objective of the present study was to prepare submicron particulate formulations of papain for pH-dependent site-specific release using pH-sensitive polymers.Methods: Enteric submicron particle formulations of papain were prepared by w/o/w emulsion solvent evaporation using hydroxypropyl methylcellulose phthalate (HPMCP), Eudragit L100, and Eudragit S100, to avoid gastric inactivation of papain.Results: Smaller internal and external aqueous phase volumes provided maximum encapsulation efficiency (75.58%–82.35%), the smallest particle size (665.6–692.4 nm), and 25%–30% loss of enzyme activity. Release studies in 0.1 N HCl confirmed the gastroresistance of the formulations. The anionic submicron particles aggregated in 0.1 N HCl (ie, gastric pH 1.2) due to protonation of carboxylic groups in the enteric polymer. Aggregates 5.0 (duodenal pH), the submicron particles showed deaggregation due to restoration of surface charge. HPMCP submicron particles facilitated almost complete release of papain within 30 minutes at pH 6.0, while Eudragit L100 and Eudragit S100 particles released 88.82% and 53.00% of papain at pH 6.8 and pH 7.4, respectively, according to the Korsmeyer–Peppas equation. Sodium dodecyl sulfate polyacrylamide gel electrophoresis and fluorescence spectroscopy confirmed that the structural integrity of the enzyme was maintained during encapsulation. Fourier transform infrared spectroscopy revealed entrapment of the enzyme, with powder x-ray diffraction and differential scanning calorimetry indicating an amorphous character, and scanning electron microscopy showing that the submicron particles had a spherical shape.Conclusion: In simulated gastrointestinal pH conditions, the HPMCP, Eudragit L100, and Eudragit S100 submicron particles showed good digestion of paneer and milk protein, and could serve as potential carriers for oral enzyme delivery. Stability studies indicated that formulations with approximately 6% overage would ensure a two-year shelf-life at room temperature.
机译:背景:颗粒系统在口服生物分子方面受到越来越多的关注。本研究的目的是使用pH敏感聚合物制备木瓜蛋白酶的亚微米颗粒制剂,用于pH依赖性位点特异性释放。邻苯二甲酸酯(HPMCP),Eudragit L100和Eudragit S100,以避免木瓜蛋白酶使胃失活。结果:较小的内部和外部水相体积可提供最大的包封效率(75.58%–82.35%),最小的粒径(665.6–692.4 nm)和25%–30%的酶活性损失。在0.1 N HCl中的释放研究证实了制剂的胃肠抵抗性。由于肠溶聚合物中羧基的质子化,阴离子亚微米颗粒聚集在0.1 N HCl(即胃pH 1.2)中。聚集体5.0(十二指肠pH),由于表面电荷的恢复,亚微米颗粒显示出聚集。根据Korsmeyer-Peppas方程,HPMCP亚微米颗粒可在30分钟内在pH 6.0下促进木瓜蛋白酶几乎完全释放,而Eudragit L100和Eudragit S100颗粒在pH 6.8和pH 7.4下分别释放88.82%和53.00%的木瓜蛋白酶。十二烷基硫酸钠聚丙烯酰胺凝胶电泳和荧光光谱证实在封装过程中可以保持酶的结构完整性。傅里叶变换红外光谱显示该酶被捕获,粉末X射线衍射和差示扫描量热法显示出无定形特征,扫描电子显微镜显示该亚微米颗粒具有球形。结论:在模拟胃肠道pH条件下,HPMCP, Eudragit L100和Eudragit S100亚微米颗粒显示出良好的消化力和乳蛋白,可以作为口服酶的潜在载体。稳定性研究表明,过量使用约6%的制剂可确保在室温下两年的保存期限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号